Our Parent Company, Fuji Pharma Co., Ltd. Receives SBTi (Science Based Targets initiative) Approval
May 07, 2025
Fuji Pharma Co., Ltd. has received official approval from the Science Based Targets initiative (SBTi) for the greenhouse gas (GHG) emissions reduction targets of Fuji Pharma Group* by fiscal year 2030 in line with 1.5C scenarios.
<GHG emissions reductions targets>
-
Reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from FY2022 base year.
-
Reduce absolute scope 3 GHG emissions from purchased goods and service 25% by FY2030 from a FY2022 base year.
By aligning with SBTi, Fuji Pharma and OLIC jointly reinforce our dedication to sustainable business practices and reducing greenhouse gas emissions to combat climate change. We will continue working collaboratively to drive meaningful contributions as part of Fuji Pharma Group and remain committed to delivering value to our stakeholders while contributing positively to the environment and society.
*OLIC (Thailand) Limited is a subsidiary and an integral part of Fuji Pharma Group. OLIC operates under the ownership and governance of Fuji Pharma Co., Ltd., aligning with strategic objectives and corporate values.
The press release for SBTi please refer to
https://www.fujipharma.jp/english/__upload/EN_fujipharma_20250507.pdf
Back to News & Events
